Patient Satisfaction with Intranasal Fentanyl for Breakthrough Pain

Patient Satisfaction with Fentanyl Sublingual Spray in Opioid‐Tolerant Patients with Breakthrough Cancer Pain

“…One other study reported TSQM scores for BTCP medication: a survey of patients ( n = 25) using intranasal fentanyl spray . Mean TSQM scores for patient satisfaction with intranasal fentanyl spray (65.6 for effectiveness, 87.0 for side effects, 58.0 for convenience, and 53.6 for global satisfaction) were lower than mean scores for fentanyl sublingual spray on 3 of the domains in the overall group in the current study (70.6, 86.1, 72.8, and 67.3, respectively).…”

Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse: Table 1

“…Recently, there has been a growing interest in the pharmacological treatment of BTcP with rapid‐onset opioids because of their pharmacokinetic properties, effectiveness, and safety [5–7].…”

The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study

“…12,13 We chose to administer fentanyl intranasally due to its ease of use in multiple settings, onset within minutes, [14][15][16][17] duration of action of around 60 minutes at maximal effect, 15,16 70% to 89% bioavailability, 18,19 and acceptability by patients. 20,21 We hoped the onset within minutes [14][15][16][17] might offer an advantage over other opioids when used in anticipation of movement, especially for activities where patients may not be able to anticipate the need for ambulation very far in advance. We also hoped the short duration of action 15,16 might avoid prolonged or excessive sedation after the stimulation of exertion was over, for this vulnerable population.…”

“…12,13 We chose to administer fentanyl intranasally due to its ease of use in multiple settings, onset within minutes, 14 –17 duration of action of around 60 minutes at maximal effect, 15,16 70% to 89% bioavailability, 18,19 and acceptability by patients. 20,21…”